Serum ADAM -17 and Interleukin-6 Levels as a Predictors in Type 2 Diabetic Patients with Myocardial Infarction Patients

Maher Adnan  Qalaf; Fadhil Jawad  Al-Tu’ma; Maher Abbood  Mukheef; Ahmed Qasim  Al-Haideri

doi:10.62472/kjps.v14.i23.63-73

المؤلفون

Maher Adnan Qalaf Clinical Chemistry Unit, Laboratory Division, Al-Hussein Teaching Hospital, Al-Hussein Medical City, Kerbala Health Directorate / Kerbala – Iraq
Fadhil Jawad Al-Tu’ma Department of Chemistry and Biochemistry, College of Medicine, University of Kerbala / Kerbala - Iraq.
Maher Abbood Mukheef Department of Chemistry and Biochemistry, College of Medicine, University of Kerbala / Kerbala - Iraq
Ahmed Qasim Al-Haideri Cardiologist, Kerbala Heart Center, Al-Hussein Medical City, Kerbala Health Directorates / Kerbala – Iraq

DOI:

https://doi.org/10.62472/kjps.v14.i23.63-73

الكلمات المفتاحية:

Disintegrin، Metallop01rotease-17، Interleukin-6, Diabetes Mellitus، Myocardial Infarction، Chronic and Acute Inflammation

الملخص

The association of heart diseases with type 2 diabetes, especially myocardial infarction, calls for a search for biomarkers that have a relationship between the two. Which facilitates the process of reducing the development of myocardial infarction in patients with type 2 diabetes. The most prominent of these associations is long-term inflammation and its first and largest factor is interleukin 6, and its close association with A disintegrin and metalloprotease 17 (ADAM-17) and its inverse relationship with type 2 diabetic patients with and without myocardial infarction. This study aims to investigate the role of ADAM-17 in the pathogenesis of diabetic type 2 Iraqi men patients with and without MI by comparing them with a apparantely helthy as control group and to see their association with interleukin-6 levels and other biomarkers. The current study was conducted on 90 Iraqi men between Ja., 2023 and Aug. 2023, 60 samples with T2DM with or without MI and the remaining 30 as apparently healthy control. The patients were selected from the visitors of the coronary care unit (CCU) and Al-Hassan Center for Diabetes and Endocrinology in Kerbala, and they were diagnosed clinically and by laboratory investigations. Various biomarkers such as ADAM-17 and IL-6 have been determined by different biochemical techniques. As a result The highest ADAM-17 and IL-6 level in type 2 diabetes without myocardial infarction was seen as comparison serum levels of IL-6, and ADAM-17 for T2DM (with or without myocardial infarction) with the control group. The correlation between IL-6 and ADAM-17 is strong in type-2 diabetes without MI and between IL-6 and electrocardiogram represented by the two types STEM and NSTEMI in type-2 diabetes with MI. In conclusion, The current study found that ADAM-17 and IL-6 have a negative effect on chronic inflammation as in T2DM without MI is more severe than acute inflammation as T2DM with MI , du to elevation of ADAM-17 and IL-6 levels in type 2 diabetic patients without MI than type 2 diabetic patient with MI.